title: Improvement of long-term survival in extensive small-cell lung cancer.
abstract: The effect of adding the epipodophyllotoxin etoposide (VP-16-213) to a standard chemotherapy regimen for patients with extensive stage small-cell lung cancer was evaluated during a randomized trial. Chemotherapy consisted of vincristine, doxorubicin, and cyclophosphamide (VAC) alone or with etoposide (EVAC). Of 139 patients enrolled, 136 patients were eligible for study and all but five were evaluable for response. The overall objective response was 46% in the VAC group v 70% in the etoposide-treated group (P = .008) with complete response (CR) rates of 12% v 29%, respectively (P = .030). Although the time to the observation of disease progression was significantly longer in the group of patients receiving etoposide (9.6 v 6.5 months, P = .010), overall survival was similar; this was probably due to administration of other agents including etoposide at the time of VAC failure. However, there were noteworthy differences in long-term (greater than or equal to 2 year) survival. Whereas only four (6%) patients treated with VAC lived 2 years, 11 (16%) of the etoposide-treated group did so (P = .100). Two-year failure-free survival was attained in one (2%) of the VAC patients and eight (11%) of the patients treated with etoposide (P = .034). Long-term survivorship, heretofore usually reported in patients with limited stage disease after a variety of treatments, may be possible with this drug combination in the setting of extensive disease.
authors.affiliation: Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC 27103.
authors.forename: D V
authors.initials: DV
authors.lastname: Jackson
authors.forename: L D
authors.initials: LD
authors.lastname: Case
authors.forename: P J
authors.initials: PJ
authors.lastname: Zekan
authors.forename: B L
authors.initials: BL
authors.lastname: Powell
authors.forename: R D
authors.initials: RD
authors.lastname: Caldwell
authors.forename: J D
authors.initials: JD
authors.lastname: Bearden
authors.forename: E C
authors.initials: EC
authors.lastname: Nelson
authors.forename: H B
authors.initials: HB
authors.lastname: Muss
authors.forename: M R
authors.initials: MR
authors.lastname: Cooper
authors.forename: F
authors.initials: F
authors.lastname: Richards
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000401:mortality; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011034:Podophyllotoxin / Q000008:administration & dosage; D011379:Prognosis; D011897:Random Allocation; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011034:Podophyllotoxin